Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218


SAN FRANCISCO & CAMBRIDGE, Mass.-- --Nov 26, 2018--Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference therapeutic for the treatment of chronic hepatitis B virus infection. The commencement of first-in-human dosing marks the first clinical use of Alnylam's Enhanced Stabilization Chemistry-Plus GalNAc conjugate delivery platform and the start of Vir's first global development program.



from Biotech News